Sanofi has consolidated 100% of Kiadis, a biopharmaceutical company that is developing a new generation of off-the-shelf NK-cell therapies to activate and stimulate the immune system. Terms of the deal were not disclosed. Previously, Sanofi owned 95.03% of Kiadis.